Authoritative, in-depth and practical financial information is here
Chairman of Yahong Pharmaceutical Pan Ke
"In the more than 10 years since its establishment, Yahong Pharmaceutical has always adhered to the road of innovation." Pan Ke, chairman of Yahong Pharmaceutical, said that the company takes innovation as the development orientation and looks for a new mechanism of action in the treatment of tumors, even if it is similar to the target of past research, the company must also make its own characteristics. Among them, the two products under development of Wei Shi Ke and Xi Wei She reflect the independent and controllable research and development strength in the development process, as well as the cooperative research and development ability and international level of the product.
Medication or surgery? If it is the same effect, most patients will choose the former. The development and technological breakthroughs in the pharmaceutical industry have brought good news to patients with many diseases and alleviated the suffering of patients to varying degrees. Yahong Pharmaceutical, which landed on the Science and Technology Innovation Board today, has been working on biopharmaceuticals for more than 10 years, and is committed to providing patients with integrated diagnosis and treatment solutions, providing patients with more choices to reduce pain in the field of genitourinary system tumor treatment.
In the view of Pan Ke, chairman of Yahong Pharmaceutical, providing such a solution is inseparable from the continuous innovation power of the enterprise. On the one hand, it is rooted in the tumor track of the genitourinary system and does specialized business research; on the other hand, it actively seeks new targets and achieves breakthroughs in differentiated thinking. "Innovation can not only alleviate the suffering of patients and contribute to human development; it can also strengthen the strength of enterprises and emerge in the competition of the industry." This is the driving force for Panko to chase the "new" all the way.
Treatment of genitourinary tumors in the first strand
"The number of new bladder cancer patients in China in 2020 is about 86,000." Pan Ke introduced that this number should not be underestimated, the incidence of bladder cancer is high, and the market demand is significant. In his opinion, bladder cancer will appear in the early stage of blood in the urine, which is relatively easy to detect and treat. With surgical resection and subsequent medications, the patient's recovery is usually ideal.
But the process is not easy. Patients with bladder cancer require postoperative perfusion therapy, usually once a week or month, intubating into the bladder without the use of anesthetics, which is accompanied by painful urination, blood in the urine, etc. Pan Ke said that the company's product Wei Shi Ke (APL-1202) is expected to slow down the pain of patients with non-muscular invasive bladder cancer, patients only need to take oral, can achieve the effect of perfusion therapy, from the current clinical trial situation, adverse reactions are expected to be greatly reduced.
"In the field of cervical precancerous lesion treatment, surgery requires the removal of a part of the cervical tissue, and there is a certain organic damage, especially for women with pregnancy plans." Pan Ke introduced that compared with surgery, The Sylvita (APL-1702) provided by Yahong Pharmaceutical can be treated by in vitro implantation, which basically does not affect the daily work and life of patients.
From the perspective of market conditions, the two drugs of Wei Shi Ke and Xi Wei She have obvious advantages. Pan Ke said that in the case of Wei Shi Ke, for example, there is currently no oral drug for the treatment of non-muscular invasive bladder cancer on the market worldwide, and there are no clinical trial stages in China, and other research products for chemotherapy that focus on recurrence of this type of cancer. "Affected by factors such as tobacco consumption, increased industrialization level and aging population, the number of new patients with bladder cancer in China may increase to 101,000 by 2025." Pan Ke believes that at present, the genitourinary system tumor lacks oral treatment programs, the demand for therapeutic drugs is increasing, and there is a relatively broad market space after the successful listing of related drugs.
Opportunities in innovation
"In the more than 10 years since its establishment, Yahong Pharmaceutical has always adhered to the road of innovation." Pan Ke said that the company is innovation-oriented, looking for new mechanisms of action in the treatment of tumors, even if it is similar to the target of past research, the company must make its own characteristics. Among them, the two products under development of Wei Shi Ke and Xi Wei She reflect the independent and controllable research and development strength in the development process, as well as the cooperative research and development ability and international level of the product.
However, Pan Ke also noted that the industry is facing two major challenges, one is the shortage of talents, it is difficult to match the development rhythm of the biopharmaceutical industry, and the other is the weak source innovation and insufficient ability to transform into new drugs. In order to support drug innovation, Yahong Pharmaceutical has established a complete R&D system covering drug discovery and mechanism research, preclinical development, pharmaceutical research, translational science research, Chinese and global clinical trials, regulations and registration declarations.
"We now have a cascade talent team system of executives, middle-level and young people." Pan Ke introduced that these executives have an average of more than 20 years of experience in the pharmaceutical industry in the subdivision field, effectively supporting the establishment of the R&D system, and leading the middle and dynamic young people with a certain level of technology to grow together. For the "small and fine" genitourinary tumor market, the company is also cultivating a professional market team.
Deep cultivation and innovation, fruitful. As of June 2021, the company has obtained 24 invention patents, including 19 overseas patents, fully docking the global technology market. Pan Ke revealed that after the above patent declaration, the company will also pay attention to the protection of scientific research results, so that competitive drugs fully reflect the market value and social value.
"The company has built three core technology platforms, including targeted immunomodulation normalization, prodrug and precision drug delivery, and targeted protein degradation based on molecular fragment assembly." Pan Ke explained that these technology platforms fully combine the actual needs of clinical front-line personnel and the research and development ideas of enterprises, and have developed a number of new drug candidates.
Anchor goals in development
"IPOs are creating new pressures and challenges for us because to make a commitment to society and investors, we have to learn to turn pressure into motivation." Pan Ke laughed and said that the listing is one of the important strategic steps of Yahong Pharmaceutical, which means that the company will move towards a new stage and seek new growth points and breakthrough points with the help of the capital market.
According to the fundraising plan, Yahong Pharmaceutical will make efforts in the direction of "new drug research and development", "production of drugs, medical devices and supporting creams", and "marketing network construction". Pan Ke said that the company will continue to develop and research around Visco, Xivita, APL-1401, APL-1501 and other products, reflecting its focus in the field of genitourinary system.
"We're not only focusing on the drug, but also looking at synergies between the product portfolios." Pan Ke admitted that although there are challenges in terms of information and utility of integrated products, the integrated diagnosis and treatment solution covering screening, detection, diagnosis, treatment and follow-up has been highly recognized by the industry. This requires companies to fully understand all aspects of the industry and choose the optimal solution.
"In the next three years, we will take Thexco, Xavi, and the two products introduced——— Hecway and UroViu Cystoscope as the main products." Pan Ke said that Yahong Pharmaceutical will promote the commercialization process of the above products and the research and development progress of other research projects in an orderly manner. Although there are certain risks in innovation, the company will step up efforts to cultivate new growth points and balance the risk points so that innovation can truly benefit users.
Edit: Qi Doudou
Proofreader: Feng Wenjun
Editor: Zhang Dawei
Producer: He Yongxin
Editor-in-charge: Shao Ziyi
Producer: Pu Hongyi
Issued: Yu Yaqin